China-Japan Friendship Hospital
cjfh.com.cnLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
172
Active
90
Phase 3
1
Total enrollment
1,195,808
Pipeline matrix
Showing 33 of 33 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| semaglutide | — | — | — | — | — | 1 | |
| Kuangxiong Aerosol | — | — | — | — | — | 1 | |
| High-dose ferric derisomaltose | — | — | — | — | — | 1 | |
| Low-dose ferric derisomaltose | — | — | — | — | — | 1 | |
| ShengXian-QuYu Decoction | — | — | — | — | — | 1 | |
| Wangbi granules | — | — | — | — | — | 1 | |
| Wangbi granules simulant | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | 2 | ||
| Shouhui Tongbian | — | — | — | — | — | 1 | |
| Lactulose Oral Solution Control Group | — | — | — | — | — | 1 | |
| Radiotherapy combined with immunotherapy | — | — | — | — | — | 1 | |
| BS-GLP group | — | — | — | — | — | 1 | |
| Macitentan 10 mg tablet, once daily. | — | — | — | — | — | 2 | |
| A Chinese herb formula--Yiwei Jiaohuang Onitment | — | — | — | — | — | 1 | |
| Rabeprazole Enteric-Coated | — | — | — | — | — | 1 | |
| LSG-Semaglutide group | — | — | — | — | — | 1 | |
| LSG-Mazdutide group | — | — | — | — | — | 1 | |
| LSG-Tirzepatide group | — | — | — | — | — | 1 | |
| Midazolam | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | — | 1 | |
| Esketamine | — | — | — | — | — | 1 | |
| Propofol | — | — | — | — | — | 1 | |
| Remifentanil | — | — | — | — | — | 1 | |
| Dachengqi decoction | — | — | — | — | — | 1 | |
| Normal Saline | — | — | — | — | — | 1 | |
| Analgesia plan for Anes. Group | — | — | — | — | — | 1 | |
| Analgesia plan for Surg. Group | — | — | — | — | — | 1 | |
| Iron Isomaltoside | — | — | — | — | — | 1 | |
| Physiological saline solution | — | — | — | — | — | 1 | |
| Yiqi Yangyin Formula | — | — | — | — | — | 1 | |
| Yiqi Yangyin Formula placebo | — | — | — | — | — | 1 | |
| JAK Inhibitor | — | — | — | — | — | 1 | |
| Calcineurin Inhibitors | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2025-08-31
- 2025-12-31
- 2026-03-01
- 2026-07-31
- 2026-08-01
- 2026-09-30
- 2026-10-01
- 2026-12-30
- 2026-12-31
Top conditions
- Chronic Obstructive Pulmonary Disease18
- Obesity8
- Bariatric Surgery6
- Pulmonary Embolism6
- Lung Cancer5
- Anemia5
- COPD Exacerbation4
- Heart Failure4
Frequently asked questions about China-Japan Friendship Hospital
- How many clinical trials does China-Japan Friendship Hospital have on ClinicalTrials.gov?
- China-Japan Friendship Hospital is listed as the lead sponsor on 172 clinical trials in ClinicalTrials.gov, 90 of which are currently active (recruiting, enrolling, or ongoing).
- How many of China-Japan Friendship Hospital's trials are in Phase 3?
- 1 of China-Japan Friendship Hospital's trials are in Phase 3, spread across 33 active drug programs.
- What therapeutic areas does China-Japan Friendship Hospital focus on?
- China-Japan Friendship Hospital's most-studied conditions on ClinicalTrials.gov are Chronic Obstructive Pulmonary Disease, Obesity, Bariatric Surgery, Pulmonary Embolism, Lung Cancer.
- When are China-Japan Friendship Hospital's next clinical trial readouts?
- China-Japan Friendship Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery”, expected around 2025-06-30.